Merus N.V. (MRUS) director options cancelled for cash after $97 tender
Rhea-AI Filing Summary
A director of Merus N.V. reported the cancellation of multiple share options in connection with a cash tender offer by Genmab. Under a transaction agreement signed on September 29, 2025, Genmab’s wholly owned subsidiary launched an offer for all issued and outstanding Merus common shares and, on December 12, 2025, accepted all shares that were validly tendered at $97.00 per share in cash.
The reporting person held several options to buy Merus common shares with exercise prices between $10.04 and $48.73. Each option was cancelled on December 12, 2025 in exchange for cash equal to the difference between the $97.00 offer price and the option’s exercise price, multiplied by the number of underlying shares. Following these transactions, the reporting person listed no remaining derivative securities related to Merus common shares.
Positive
- Genmab tender offer accepted at $97.00 per Merus common share, setting a clear cash value for tendered shares and related option payouts.
Negative
- None.
Insights
Genmab’s cash tender offer leads to cancellation and cash-out of a Merus director’s share options.
Merus N.V. entered into a transaction agreement with Genmab A/S on September 29, 2025, under which Genmab’s wholly owned subsidiary commenced a tender offer for all issued and outstanding Merus common shares. On December 12, 2025, the purchaser accepted all shares that were validly tendered and not properly withdrawn at an offer consideration of $97.00 per share in cash, subject to applicable withholding taxes.
The reporting director held several share options with exercise prices ranging from $10.04 to $48.73, covering blocks such as 17,000 and 13,193 Merus common shares. Each option was cancelled on December 12, 2025 and converted into a cash payment equal to the amount by which the $97.00 offer consideration exceeded the option’s exercise price, multiplied by the aggregate number of underlying shares. After these cancellations, the filing shows zero derivative securities beneficially owned.
This structure monetizes the director’s equity incentives directly off the tender offer price, aligning the option payout mechanics with the cash consideration available to participating common shareholders at the acceptance time. Subsequent company disclosures may provide additional detail on the overall transaction structure and any remaining steps following the tender offer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Share Option (right to buy) | 13,193 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 8,844 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 14,414 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 16,604 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 6,120 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 8,631 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 17,000 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 5,650 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 4,983 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 8,500 | $0.00 | -- |
Footnotes (1)
- On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
FAQ
What insider transaction did Merus N.V. (MRUS) report on December 12, 2025?
A director of Merus N.V. reported that multiple share options were cancelled on December 12, 2025 in connection with a cash tender offer and were settled in cash instead of remaining outstanding.
Does the reporting person still hold Merus N.V. derivative securities after these transactions?
No. After the cancellations on December 12, 2025, the filing shows zero derivative securities beneficially owned by the reporting person related to Merus common shares.
When was the transaction agreement between Merus N.V. and Genmab signed?
The transaction agreement between Merus N.V. and Genmab A/S, together with Genmab’s wholly owned subsidiary, was signed on September 29, 2025.